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Abstract
The diagnosis of Systemic Lupus Erythematosus (SLE) is challenging due to its heterogeneous clinical presentation and the
lack of robust biomarkers to distinguish it from other autoimmune diseases. Further, currently used laboratory tests do not
readily distinguish active and inactive disease. Several groups have attempted to apply emerging high throughput profiling
technologies to diagnose and monitor SLE. Despite showing promise, many are expensive and technically challenging for
routine clinical use. The goal of this work is to develop a better diagnostic and monitoring tool for SLE. We report a highly
customisable antibody microarray that consists of a duplicate arrangement of 82 antibodies directed against surface
antigens on peripheral blood mononuclear cells (PMBCs). This high-throughput array was used to profile SLE patients
(n=60) with varying disease activity, compared to healthy controls (n=24), patients with rheumatoid arthritis (n=25), and
other autoimmune diseases (n=28). We used a computational algorithm to calculate a score from the entire microarray
profile and correlated it with SLE disease activity. Our results demonstrate that leukocyte-capture microarray profiles can
readily distinguish active SLE patients from healthy controls (AUROC=0.84). When combined with the standard laboratory
tests (serum anti-dsDNA, complements C3 and C4), the microarrays provide significantly increased discrimination. The
antibody microarrays can be enhanced by the addition of other markers for potential application to the diagnosis and
stratification of SLE, paving the way for the customised and accurate diagnosis and monitoring of SLE.
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Introduction
Systemic Lupus Erythematosus (SLE) is an immune-mediated,
multisystem, inflammatory disease characterised by autoantibody
production. Its diagnosis relies on identification of combinations of
clinical features and laboratory tests to distinguish it from other
autoimmune disorders [1]. This is often problematic in clinical
practice as some of the features required to fulfill the diagnostic
criteria may take years to develop and some individuals with
pathognomonic features do not meet all the established criteria.
The clinical course of the disease is typified by unpredictable flares
manifest by the onset of new organ involvement, worsening of
existing disease, and periods of remission. Although several
laboratory measurements, such as serum complement C3 and
C4 levels, anti-dsDNA antibody titers and erythrocyte sedimen-
tation rate (ESR) are routinely used in the clinic to help with
disease management, individually they are not diagnostic of SLE
and do not on their own give an accurate indication of disease
activity. Consequently, assessment of disease activity and response
to therapy remains largely clinical. The development of reliable
biomarkers would enable us to distinguish between SLE and other
autoimmune or infective conditions with similar clinical presen-
tations, and would assist in the diagnosis and management of the
condition. Such markers would ideally stratify the condition,
predict flares, determine disease severity and activity, and response
to therapy, and thereby limit unnecessary investigation and
exposure to the side effects of immunosuppressive agents.
By using gene transcripts grouped into modules, Chaussabel et
al. [2] developed a bioinformatics system to monitor disease
activity in SLE. Their results raise the possibility of more precise
characterisation of disease activity based on the pathogenesis of the
condition and its molecular expression. However, the high cost,
need for batch analysis and the delays in acquisition of results of
molecular analyses using current technology limits the clinical
utility of this approach for individual patients.
Autoantibodies are the hallmark of many autoimmune diseases.
To circumvent the limitations of the DNA gene array, many
groups [3–6] have employed miniaturised formats of parallel
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particular interest, Robinson et al. [4] fabricated 1152-feature
arrays containing 196 distinct biomolecules representing major
autoantigens targeted by autoantibodies from patients with
autoimmune rheumatic diseases and found them to be of
comparable sensitivity and specificity to conventional assays.
Fattal et al. [7] used an array to measure antibodies to 930 different
antigens including viral proteins in 40 SLE patients and
successfully identified particular combinations of markers specific
for the disease at various levels of activity. They quoted a
sensitivity of .93% and specificity of .88% in distinguishing SLE
from normal controls.
Belov et al. demonstrated the utility of leukocyte-capture
antibody microarrays in the diagnosis, monitoring and stratifica-
tion of patients with lymphoproliferative diseases [8,9]. The
concept was co-invented by one of the authors (CGdR) and has
been successfully employed to identify different clonally expanded
leukocytes populations that are characteristic of human leukaemias
[8,9]. However, it soon became clear that these cell capture
microarrays could also be used to detect more subtle changes in
leukocyte populations, for example cell activation or inflammatory
changes in patients with heart disease and other inflammatory
diseases [10–15]. We postulated that inflammatory diseases such
as SLE would also cause changes to the expression of leukocyte
surface molecules that could be detected by the cell array. To
demonstrate the potential utility of this microarray in the diagnosis
and stratification of SLE, we conducted a study of patients with
SLE and demonstrated that the leukocyte capture array profile of
these patients is readily distinguishable from that of healthy
controls. By generating an immunophenotypic fingerprint for each
patient, the cell capture microarray can identify common patterns
that permit identification of subgroups based on disease activity.
Notably, we show that our microarray can on its own distinguish
SLE from healthy controls and can complement standard
laboratory tests to improve stratification of SLE patients based
on disease activity. Further customisation with other antibodies,
based on knowledge of leukocytes surface antigen expression
related to pathogenesis of SEL, is likely to improve the sensitivity
and specificity of the array.
Methods
Microarray construction
Antibody microarrays (DotScan
TM) were purchased from
Medsaic Pty. Ltd., Sydney. The construction of the antibody
microarray has been described previously [8]. It consists of a
duplicate set of 82 mouse monoclonal antibodies directed against
human cluster of differentiation (CD) antigens that are robotically
placed on the surface of a nitrocellulose-coated glass slide
(Schleicher and Schuell, FAST slides). The slides and the
antibodies, including the appropriate isotype control antibodies,
are listed in Figure S1. Unoccupied binding sites on the remaining
surface of the slide are then blocked using powdered skim milk to
minimise non-specific binding. A set of mouse isotype control
antibodies is included, and the perimeter of the CD antibody array
is marked by anti-CD44, a pan-leukocyte CD antibody, used to
show that leukocytes are evenly distributed across the antibody
area. Only 10 nL of each antibody is required for each spot,
which, once deposited on the nitrocellulose surface, spreads to a
diameter of 450–500 mm. This is large enough to accommodate
up to 1500 leukocytes, providing an acceptable statistical sampling
of the population of cells applied to the array surface. After 30
minutes any leukocytes that are not immobilized at the antibody
dots are removed by gentle washing, the slide is scanned, and the
attached cells are quantified by light scattering [8]. We previously
reported a good correlation between the dot intensities on
antibody microarrays and flow cytometry with the same antibodies
[8], but both the production of the microarrays and the
nitrocellulose slides have changed since this was published.
Accordingly, we have included new data from the batch of
antibody microarrays to those used in the experiments report in
this paper. PBMCs from a healthy blood donor were stimulated by
overnight exposure to anti-CD3 monoclonal antibody and then
applied to microarrays and quantified by densitometry as
described above and also monitored by flow cytometry. The
microarray spot densities for four randomly selected expressed
antigens (CD25, CD69, CD71 and HLA-DR) are well matched by
the cell numbers determined by flow cytometry from the same
sample (Figure S2).
Patients
Written informed consent was obtained from 117 subjects
attending clinics of the Royal Prince Alfred Hospital. 137
assessments were performed: 60 on patients with SLE, 53 with
other autoimmune diseases including rheumatoid arthritis (RA)
(N=25), vasculitis (N=9), polymyositis (N=1), seronegative
arthritis (N=8), scleroderma (N=3), Sjogren’s syndrome (N=1),
undifferentiated connective tissue diseases (N=6), and 24 healthy
controls. All SLE patients fulfilled at least four of the American
College of Rheumatologists (ACR) criteria for the disease [1] and
their disease activity was determined according to the SLE Disease
Activity Index (SLEDAI) score [16]. We assigned patients into
three disease activity groups according to their SLEDAI score with
$8 defined as clinically active, 5–7 as intermediate (semi-active)
activity and, #4 as inactive. The details of their immunosuppres-
sive medications were recorded at the time of each clinic visit.
Thirty three (55%) patients had inactive disease, 16 (27%) had
intermediate disease activity, usually following treatment of a
disease flare, and 11 (18%) were clinically active. There were no
differences between the demographics of the patients in any of the
clinical categories, their use of immunosuppressants at the time of
study or the number of ACR criteria fulfilled during the course of
their illness (Table 1). The results of anti-dsDNA antibodies (Farr
assay, Trinity Biotech, Ireland) and serum complements C3 and
C4 levels (ImmageH 800, Beckman Coulter) were recorded at each
visit. The project was approved by the Royal Prince Alfred
Hospital Ethics Committee (Approval number X06-0089).
Blood processing and microarray profiling
Anticoagulated whole blood was collected in EDTA tubes from
each participant and maintained at room temperature until use
within 24 hours. Leukocytes from peripheral blood mainly
consisting of peripheral blood mononuclear cells (PBMCs) were
isolated using Histopaque (Sigma-Aldrich), washed in PBS,
resuspended in PBS containing 1 mM EDTA to a density of 10
7
cells/ml, and incubated on the cell array for 30 min at room
temperature; unbound cells were then gently washed off with PBS.
Arrays were then fixed for at least one hour in PBS containing 1%
(v/v) formaldehyde (Sigma-Aldrich) washed in PBS, scanned, and
the light scattering by the attached cells recorded in an image file.
The microarray data is accessible at National Center for
Biotechnology Information (NCBI)’s Gene Expression Omnibus
(Accession number: GSE27293).
Preprocessing of microarray expression data
The raw intensity light scatter values at each spot on the slide
were scale-normalised such that the expression value for each CD
antigen is between 0 and 10. This normalisation method has been
Cell-Capture Antibody Microarray for SLE
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with corresponding cell counts by flow cytometry [11]. Further, we
applied two filtering criteria to the data: Firstly, antigens that had
low expression across all samples were excluded. An antigen was
deemed to have low expression if its median expression value
among the 20% most highly expressed samples was less than 1,
since this is approximately the lower limit of the technology to
reliably detect antigen binding [11]. Secondly, CD antigens that
had a low signal-to-noise ratio (SNR) were rejected. The SNR of
an antigen was defined as the ratio of the standard deviation of its
mean expression value across all samples against the mean
absolute difference between the two intra-slide replicate measure-
ments across all samples. CD antigens with a SNR less than 1.2
were filtered out since this ratio appeared to be a conservative
threshold that filtered out most of the negative control spots on the
array.
Individual CD antigen biomarkers for SLE
To identify CD antigens that individually showed strong
evidence of association with the class label (e.g., SLE or control),
we performed a linear model analysis using the R package, limma
[17], which is a program specifically designed for microarray
analysis. A p value was calculated using the moderated t statistics
for each CD antigen to determine whether it was statistically
significant. We also calculated the Area Under the Receiver
Operating Characteristic (AUROC) curve for each CD antigen.
This analysis was performed using the R package ROCR [18].
We tested whether the expression levels of each individual CD
antigen were significantly associated with SLE activity using a
moderated t test and AUROC. Six sets of comparisons were
performed to assess whether each individual marker was good for
diagnosis or stratification of SLE. A CD antigen qualified as a
singleton biomarker if it had p,0.05 and AUROC.0.7 in any
comparison.
Measurement of SLE activity based on the multiple
biomarkers
We used an advanced classification algorithm, Support Vector
Machine (SVM) [19,20] to create an SLE activity score from the
entire antigen expression profile. We used the SVM implemen-
tation in the R package e1071 with default parameters (kernel=-
radial basis kernel, cost=1). Briefly, a SVM uses labelled training
examples to construct a non-linear decision rule (i.e., a decision
boundary) that can best distinguish the expression profiles of SLE
patients from those of healthy controls. We assumed there is a
linear trend in SLE disease activity; therefore we trained the SVM
model using profiles from healthy controls and active SLE patients
only. Once the SVM model was trained we calculated an SLE
activity measure, which we refer to as an S-score, for every
expression profile, x, based on the profile’s distance, f(x), from the
decision boundary as determined by the SVM classifier. The S-
score is calculated by the following formula:
Sscore~exp({f(x))
Cross-validation
We used a three-fold repeated sub-sampling cross-validation
strategy to assess the performance of the SLE activity score.
Briefly, we iteratively performed the following steps 100 times:
randomly partitioned the samples into three equal portions and
used two of these portions as the training set to build a SVM
model. The remaining portion was a testing set to assess the
model’s sensitivity and specificity for each of the three SLE activity
states. An ROC curve and an AUROC value were generated at
each iteration and the mean and standard deviation of AUROC of
the 100 iterations were recorded.
Table 1. Demographic and clinical characteristics of the patients.
SLE active SLE intermediate SLE inactive
Number 11 16 33
Demographics
Age, mean (range), years 43 (36–59) 36 (28–48) 47 (24–80)
Female (%) 10/11 (91%) 14/16 (88%) 29/33 (88%)
Caucasian 8 (73%) 11 (69%) 26 (79%)
Asian 3 (27%) 5 (31%) 7 (21%)
No of ACR criteria fulfilled 6 6 7
Laboratory criteria
Anti dsDNA positive
* 10(91%) 9 (56%) 8 (24%)
C4
* 7 (64%) 7 (44%) 7 (21%)
C3
* 7 (64%) 10 (63%) 8 (24%)
Medications
No immunosuppressants 3(27%) 2 (13%) 10(30%)
Prednisone alone 1(9%) 3 (19%) 7 (21%)
Immunosuppressants alone 2(18%) 1 (6%) 3 (9%)
Prednisone+immunosuppressants 5(45%) 10 (63%) 13(39%)
*at time of assessment
doi:10.1371/journal.pone.0058199.t001
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Analysis of singleton biomarkers for SLE
After the normalisation and filtering steps, 57 antibody spots
passed our quality filters and were used in subsequent analyses.
The results demonstrate (Table 2) that many T and NK-cell
surface markers are down-regulated in SLE. Another important
observation was that, although many of these CD antigens have
statistically significant associations with the disease, none are good
biomarkers of SLE activity because the AUROC values are not
sufficiently high (,0.85), and do not positively correlate with
disease activity. This indicates that no CD antigen alone, as
measured by our antibody microarray, can be used as a reliable
biomarker for monitoring the activity of SLE. We performed the
same moderated t test and ROC analysis for each of the
conventional laboratory markers (anti-dsDNA, complement C3
and C4), and found that they can generally differentiate patients
with inactive SLE from those with active forms of SLE, but cannot
reliably distinguish semi-active patients and active ones (Table 2).
In particular, anti-dsDNA and C3 show reasonable discriminatory
ability that no single marker in the current version of the
microarray can match.
The heat map in Figure 1A shows the expression pattern of
singleton CD antigen biomarkers. Hierarchical clustering reveals
two large clusters of profiles, one dominated by SLE patients (left
hand side of Figure 1A), and one dominated by healthy subjects
(right side of Figure 1A). Although the clustering analysis cannot
perfectly separate the SLE patients from healthy controls, the
results suggest that the antigen profiles contain useful discrimina-
tory information for building a diagnostic test.
To investigate whether the set of CD biomarkers contained
redundancy (by having multiple biomarkers with highly correlated
expression patterns), we performed a Pearson’s correlation
coefficient among the expression profile of all singleton CD
antigen biomarkers listed in Table 2. Figure 1B shows that there
are several strongly co-expressed clusters of CD antigens among T
cell (CD7, CD5, CD3, and CD2), NK cell (CD56, CD57) and B
cell markers (kappa, lambda). Some of the CD antibodies that
produced highly correlated antigen expression profiles can
therefore be selectively removed from the microarray without
decreasing its predictive value. It is well known in the machine
learning literature that the best feature sets for classification are
those that individually are strongly associated with the class label,
but are unrelated to each other. The conventional serum
biomarkers such as C3, C4 and anti-dsDNA measured in the
patient cohort have little correlation with other CD biomarkers in
the study, suggesting that they can provide complementary
information in the assessment of SLE.
Leukocyte capture arrays can discriminate SLE from
healthy subjects
Next we explored whether building a SLE classification rule
based on the expression of multiple antigens can result in a more
accurate and robust diagnostic assay. We built a multivariate
classifier for our microarray profile using SVM, and validated the
classification performance using rigorous cross-validation. We used
this SVM classification approach to construct a SLE diagnostic
score, called the S-score, using expression of all the 57 CD
antigens measured, and assessed the quality of the S-score using
cross-validation. The ROC plots in Figure 2A demonstrate that
inactive SLE cannot be reliably separated from healthy controls,
but semi-active and active SLE patients can (AUROC=0.83 and
0.84 respectively). In addition, we also investigated whether the S-
score is positively correlated with SLE disease activity. The
average S-score of the samples belonging to the four classes
(healthy, SLE inactive, SLE semi-active and SLE active) from the
100 rounds of cross-validation are summarised in Figure 2B, and
demonstrate a positive correlation between the S-score and disease
activity. This is a particularly encouraging finding since the SVM
model was trained using samples from healthy subjects and active
SLE patients only, but it correctly identified the relative disease
activity of semi-active and inactive patients, which supports the
robustness of this approach.
We also investigated whether the antibody array can distinguish
SLE patients from patients with other autoimmune diseases. In
this analysis, we independently built a two-class SVM classifier for
each comparison (RA vs. healthy, RA vs. SLE inactive, RA vs.
SLE semi-active and so on) as shown in Figure 2C. These analyses
show that active and semi-active SLE can be reliably distinguished
from healthy controls with an AUROC greater than 0.8 (black
Figure 1. SLE singleton biomarker analysis. (A) Heat map of singleton CD biomarkers from SLE patients and healthy controls. (B) Heat map of
Pearson’s correlation coefficient between each pair of CD biomarkers and conventional laboratory biomarkers.
doi:10.1371/journal.pone.0058199.g001
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autoimmune diseases and RA compared to healthy subjects and
RA compared to active SLE, have AUROC values between 0.7
and 0.8 (between the black solid and dotted lines) that indicate
discrimination with less certainty, while the remainder of the
diseases with AUROC values ,0.7 (to the left of the solid black
line (e.g., RA and other autoimmune diseases vs. SLE inactive etc)
cannot be reliably distinguished.
Leukocyte capture arrays improve the discriminative
ability of conventional laboratory tests in SLE
Currently the assessment of SLE activity is based on a
combination of clinical symptoms, signs, and laboratory tests.
Since discriminating inactive SLE from more active forms of SLE
(i.e., semi-active or active) may be important in management, we
evaluated the discriminatory ability of combination of tests
including antibody arrays and the serological and immunochem-
ical tests performed. For each of the datasets, we trained a classifier
using the SVM approach, and its discriminatory ability was
Figure 2. Cross-validation analysis of a SVM based classifier for diagnosis and stratification of SLE. (A) ROC analysis of the SLE
classification measure. (B) The average S-score of test samples from 100 rounds of cross-validation (error bar represents S.E.M). (C) Average AUROC of
comparisons between SLE, healthy controls, rheumatoid arthritis (RA) and other autoimmune diseases (others). The black dotted line at AUROC=0.8
indicates a classifier that can readily separate the two classes, and a black solid line at AUROC=0.7 indicates a classifier that is moderately effective for
separating two classes (error bar represents S.E.M).
doi:10.1371/journal.pone.0058199.g002
Figure 3. Comparison of discriminatory ability of CD antibody microarray and conventional laboratory tests.
doi:10.1371/journal.pone.0058199.g003
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The serum tests, anti-dsDNA antibodies, C3, and C4 levels, are
more discriminating than our antibody microarray (p,0.001, one-
sided paired t test) in distinguishing semi-active and active SLE
from inactive SLE (Figure 3A and B). However, our antibody
microarray can better distinguish active from semi-active SLE
(p,0.001). When we trained a SVM based on the results of both
microarray and the serum tests, we achieved a significantly better
separation of semi-active SLE from inactive and active SLE
(p,0.001 for both classification tasks). Given the clinically
heterogeneous presentation of SLE patients, it is particularly
encouraging to note that the microarray can improve the
discriminative ability of conventional laboratory tests for semi-
active vs. inactive SLE. Taken together with the observation that
nearly all singleton CD biomarkers have very low expression
correlation with the measurements from the three conventional
laboratory tests (Figure 1B), we believe that the leukocyte
microarray does indeed provide additional information.
Discussion
This antibody microarray yields comparable diagnostic sensi-
tivity and specificity to the DNA microarray system described by
Chaussabel et al. [2]. The antibody microarray we described is,
however, a potentially more practical platform for use in the
diagnostic laboratory, since the analytical equipment required is
less technically challenging and much less expensive (cost per
microarray is ,US$90) than gene expression microarrays or flow
cytometry for the same number of antibodies, and it can be
performed rapidly on an ad hoc basis. Traditionally, cellular
markers and populations (and more importantly the changes in
these populations) are detected by flow cytometry. This is
generally a technically challenging, slow and expensive method
that, when performed in a sophisticated laboratory with large
sample volumes of sera and reagents and skilled technicians, can
analyze no more than 17 CD antigens in a single analysis. The cell
capture microarrays, in contrast to flow cytometry, can be
performed on the bench in any laboratory and can simultaneously
determine the presence of more than 100 antigens expressed on
the surface of leukocytes. Furthermore, the microarray provides a
semi-quantitative method of monitoring the numbers of cells in a
sample since the light scattering from the cells is proportional to
the number of cells immobilized on the arrays [8,11]. In our
experience, the method requires minimal training and uses only
small volumes of antibodies and peripheral blood. In addition to
the discriminatory ability demonstrated in this study, the technical
simplicity of this profiling technology makes it attractive for clinical
use.
The high-throughput nature of this microarray is also partic-
ularly attractive because it allows rapid identification of an
immunophenotype for each patient based on the expression of
multiple cell surface molecules that have been perturbed due to
current or previous activation events in SLE. In principle,
combinations of expressed surface membrane proteins (CD
antigens and other membrane proteins) characterise functional
subsets of leukocytes. One key idea of this study is that such
leukocyte surface markers carry useful information about SLE
activity. Our data represent a proof of concept only and will need
to be validated using a much larger sample size before the
microarray is applied in a clinical setting.
It is possible to turn our antibody microarray approach on its
head, namely to immobilize the antigen and capture the
antibodies as undertaken by Fattal et al. [7] and Robinson et al.
[4]. Although these methods can distinguish SLE from healthy
controls, their clinical performance in distinguishing SLE from
other autoimmune and rheumatic has not been demonstrated and
performance characteristics in the clinic are not yet reported. Our
pilot study demonstrates that leukocyte surface markers contain
information that may be used alone or in combination to other
markers (such as anti-dsDNA) to distinguish SLE from normal
controls, stratify disease activity, and may even distinguish SLE
from other autoimmune and rheumatic conditions, although the
later requires further study.
We show that a disease activity score can be constructed based
on the entire antigen expression profile through a state-of-the-art
machine learning technique. Similar supervised machine learning
approaches for clinical diagnostic support using microarray
technology have been reported extensively in the last decade,
particularly in the field of cancer classification [21,22]. Unlike a
traditional singleton biomarker, the calculation of our S-score
depends on the size and quality of the training examples. Different
SVM decision functions are generated by using different training
samples. Therefore, we performed a cross-validation analysis to
estimate the sensitivity and specificity of this classifier for SLE.
This analysis indicates that our approach for generating the S-
score is generally robust even when different subsets of the training
samples are used.
We note that some CD antigens, including CD95 [23], CD86
[24,25], which have previously been reported to be associated with
SLE, do not show statistical significance in our singleton
biomarker analysis. This is surprising given their role in co-
stimulation and cell activation. We suspect this may reflect the lack
of specificity of the clone of antibodies used in this version of the
microarray. From our experience, different clones of antibodies
have different antigen-binding characteristics, and further exper-
iments using different antibody clones will determine if alternative
antibodies will contribute to the discriminatory ability of the array.
Although the discriminatory ability of the current version of the
microarray on its own is no better than conventional tests, the fact
that the microarray provides additional information for clinical
assessment of SLE is an important finding. The expression values
from about 40% of the antibody spots in the current version of the
microarray were filtered out because of low expression or high
variability in performance. This is not surprising as this version of
microarray was originally designed for the diagnosis of lympho-
proliferative diseases [8]. It is likely that a customised antibody
microarray containing rationally selected antibodies that target
CD antigens known to reflect the pathogenesis and activity of SLE
will improve the sensitivity and specificity of the antibody
microarray [26]. In particular, we propose that a customised
SLE antibody microarray can be developed by retaining only
those informative biomarkers in the current generation of the
array, and augmenting the array with other antibodies directed to
cell surface markers whose expression has been reported to be
perturbed in patients with SLE. These could include antibodies
related to innate immunity (CD1a, CD14, CD83), adaptive
immunity (CD161), adhesion molecules (CD166 and CD6), other
markers (CD279 and other chemokines e.g., CCR6). These and
other molecules have been shown to be potentially involved in the
pathogenesis of SLE and may therefore also be useful markers of
the disease and level of activity [26,27].
Conclusion
Our observations using a first-generation antibody microarray
demonstrate that SLE patients can be distinguished from healthy
controls based on the differential expression of CD markers on
PBMCs. Our analysis indicates that the current version of PBMC
Cell-Capture Antibody Microarray for SLE
PLOS ONE | www.plosone.org 7 March 2013 | Volume 8 | Issue 3 | e58199CD antibody microarray can be combined with current labora-
tories tests to provide superior discriminatory ability to stratify
SLE patients according to disease activity. We postulate that the
addition of rationally selected antibodies based on reports of their
altered expression in SLE will result in an even higher
discriminatory ability than currently used tests, with potential
benefits both for diagnosis and monitoring of disease and tailoring
of therapy.
Supporting Information
Figure S1 An image of the scanned microarray from a
healthy control and SLE patients with different disease
activity.
(TIFF)
Figure S2 Validation of expressed microarray CD
antigen markers using flow cytometry. (A) Unnormalized
microarray spot intensity of four randomly selected expressed CD
antigens in CD3 stimulated leukocytes. (B) Flow cytometry
analysis of the same four antibodies in the same cell population,
and also controls. All four measured expressed CD antigens
detected by the microarray are also detected as being expressed by
flow cytometry.
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